Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms
But a US federal judge ruled last month that UMC and Fujian Jinhua can review Micron’s evidence against them in the Special Administrative Region
Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019
Seattle Genetics is demanding rights to Daiichi Sankyo’s potential blockbuster cancer treatment, which it says is an improvement on the proprietary technology included in their previous partnership
Top firms in chemicals, materials and other industrial fields from Japan have not been shy about suing Chinese competitors, but China’s patent office has been a big obstacle to enforcement
New market entrants, 5G futures, trade secret challenges, top dealmaking tips, the end of the foundry patent war, a new billion dollar IP fund and much more discussed at the sell-out event in Tokyo
Centrient’s head of IP lifts the lid on why the company has been putting more focus on IP enforcement in India and explains the attractions of trade secrets
Numbers also show that damages are rising. But litigation statistics only tell part of the story on plaintiff success.
The number of grants also drops while UK sees worrying fall in applications; but study has good news for EPO President Campinos
Eight Chinese entities – including leaders in AI, facial recognition and data forensics - added to Bureau of Industrial Security entity list
Our round-up of all the major IP developments affecting the life sciences industries last month
Taiwanese maker of smartphone lenses is now wielding patents against not just a rival supplier but its end customer HP
Taiwan’s Personal Genomics is going after an acquisition target of Illumina, the top player in the sequencing space
Comments by Deputy Assistant Attorney General in interview also suggests that the US will continue to take a more proactive approach to policing security risks in telecoms networks
Legal and commercial developments suggest that disputes over increasingly valuable biopharma know-how, proprietary information and data will increase in years to come.